Prostacyclin immobilized albuminated surfaces.

Area of Science:

• Biomaterials Science
• Thrombosis Research
• Surface Chemistry

Background:

• Platelet adhesion to artificial surfaces is a primary cause of thrombosis.
• Existing antiplatelet agents like prostaglandins have short half-lives.
• Developing surfaces that inhibit platelet adhesion is crucial for medical devices.

Purpose of the Study:

• To create novel biomaterial surfaces that resist platelet adhesion and aggregation.
• To evaluate the efficacy of modified polyetherurethane urea (PEUU) surfaces incorporating a stable prostacyclin analog and polyelectrolyte.
• To assess the anti-thrombotic potential of these modified surfaces.

Main Methods:

• Modification of polyetherurethane urea (PEUU) surfaces by immobilizing 10,10-difluoro-13-dehydroprostacyclin (DF2-PGI2) and polyelectrolyte (PE).
• Glow discharge technique was employed for surface modification.
• Platelet adherence assays were performed with and without inducing agents (fibrinogen, thrombin, ADP).
• Protein interaction studies using 125I-labeled albumin and fibrinogen.

Main Results:

• Modified PEUU surfaces exhibited negligible platelet adherence.
• Significant inhibition of platelet adherence was observed even in the presence of thrombogenic agents.
• The modified surfaces showed reduced interaction with fibrinogen compared to unmodified surfaces.
• Albumin interaction was also studied to understand surface biocompatibility.

Conclusions:

• Surface modification of PEUU with DF2-PGI2 and PE effectively retards platelet adhesion and aggregation.
• These novel biomaterials show significant potential for reducing thrombosis in medical applications.
• The developed surfaces offer improved biocompatibility for blood-contacting devices.